Amalgamated Bank Sells 1,847 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Amalgamated Bank lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 31,781 shares of the medical equipment provider’s stock after selling 1,847 shares during the quarter. Amalgamated Bank’s holdings in Lantheus were worth $3,488,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LNTH. GAMMA Investing LLC grew its holdings in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares during the last quarter. Signaturefd LLC grew its holdings in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the last quarter. Nkcfo LLC bought a new stake in Lantheus during the 2nd quarter worth about $47,000. UMB Bank n.a. grew its holdings in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new stake in Lantheus during the 3rd quarter worth about $51,000. Institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

LNTH has been the topic of several recent research reports. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Friday. B. Riley raised their target price on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. Finally, Truist Financial reaffirmed a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Insiders Place Their Bets

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $87.50 on Friday. The company has a market capitalization of $6.08 billion, a price-to-earnings ratio of 14.56 and a beta of 0.51. The firm’s 50 day simple moving average is $107.33 and its 200 day simple moving average is $95.91. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $378.73 million for the quarter, compared to the consensus estimate of $373.58 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Equities research analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.